```
=> b reg
FILE 'REGISTRY' ENTERED AT 11:21:06 ON 11 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 FEB 2004  HIGHEST RN 648858-13-3
DICTIONARY FILE UPDATES:  10 FEB 2004  HIGHEST RN 648858-13-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que stat l2
L1            50 SEA FILE=REGISTRY ABB=ON  PLU=ON  (YADAIFTNSYRKVLGQLSARKLLQDIMS
                 RQQGESNQERGARARL)/SQEP
L2             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  L1 AND C224H366N72O67S/MF


=> d his

     (FILE 'HOME' ENTERED AT 11:15:56 ON 11 FEB 2004)

     FILE 'REGISTRY' ENTERED AT 11:16:00 ON 11 FEB 2004
                E YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL/SQEP
L1            50 S E3
L2             2 S L1 AND C224H366N72O67S/MF

     FILE 'HCAPLUS' ENTERED AT 11:20:04 ON 11 FEB 2004
L3             2 S L2

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:20:15 ON 11 FEB 2004
L4             1 S L2

     FILE 'STNGUIDE' ENTERED AT 11:20:38 ON 11 FEB 2004

     FILE 'REGISTRY' ENTERED AT 11:21:06 ON 11 FEB 2004

=> d sqide can l2 tot

L2    ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2004 ACS on STN
RN    261620-11-5  REGISTRY
CN    L-Leucinamide, N-[(3-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L-α-
      aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-
      seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-
      leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-
      α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-
      glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-
      α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl-
```

(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL **44**
NTE modified (modifications unspecified)

SEQ 1 YADAIFTNSY RKVLGQLSAR KLLQDIMSRQ QGESNQERGA RARL
========== ========== ========== ========== ====
HITS AT: 1-44

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF **C224 H366 N72 O67 S**
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:257949

REFERENCE 2: 132:217510

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 261620-06-8 REGISTRY
CN L-Leucinamide, N-[(2-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl-
(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL **44**
NTE modified (modifications unspecified)

SEQ 1 YADAIFTNSY RKVLGQLSAR KLLQDIMSRQ QGESNQERGA RARL
========== ========== ========== ========== ====
HITS AT: 1-44

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF **C224 H366 N72 O67 S**
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:257949

REFERENCE 2: 132:217510

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:22:15 ON 11 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Feb 2004 VOL 140 ISS 7
FILE LAST UPDATED: 10 Feb 2004 (20040210/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d all tot l3 DISPLAY FOR HCAPLUS

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:748783 HCAPLUS
DN 137:257949
ED Entered STN: 03 Oct 2002
TI Growth hormone releasing factor analogs with increased biological potency and their therapeutic uses
IN Gravel, Denis; Habi, Abdelkrim; Brazeau, Paul
PA Theratechnologies Inc., Can.
SO U.S., 32 pp., Cont.-in-part of U. S. 6,020,311.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K038-25
ICS C07K014-60
NCL 514012000
CC 2-2 (Mammalian Hormones)
Section cross-reference(s): 34
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6458764	B1	20021001	US 1999-389486	19990903
	US 5861379	A	19990119	US 1996-702114	19960823
	US 5939386	A	19990817	US 1996-702113	19960823
	US 6020311	A	20000201	US 1998-148982	19980908
	CA 2342070	AA	20000316	CA 1999-2342070	19990907
	WO 2000014236	A2	20000316	WO 1999-CA816	19990907
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9955007	A1	20000327	AU 1999-55007	19990907
	AU 755852	B2	20021219		
	BR 9913515	A	20010605	BR 1999-13515	19990907
	EP 1109909	A2	20010627	EP 1999-941349	19990907
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

	JP 2002524472	T2	20020806	JP 2000-568979	19990907
PRAI	US 1995-453067	B2	19950526		
	US 1996-651645	B2	19960522		
	US 1996-702113	A2	19960823		
	US 1996-702114	A2	19960823		
	US 1998-148982	A2	19980908		
	US 1999-389486	A	19990903		
	WO 1999-CA816	W	19990907		

AB The present invention relates to chimeric fatty body-GRF analogs with increased biol. potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

ST growth hormone releasing factor analog prepn therapeutic use

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anabolism, improvement of; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Bone, disease
(fracture, healing of; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Diagnosis
(of growth hormone deficiencies; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Dwarfism
(pituitary, treatment; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Antiobesity agents
Human
Wound healing
Wound healing promoters
(preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Growth disorders, animal
(retarded, treatment; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Pituitary gland, anterior lobe
(somatotroph, overall upgrading of somatotroph function; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Osteoporosis
(therapeutic agents; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Obesity
(treatment; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 9002-72-6, Somatotropin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(deficiency, treatment; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 9034-39-3DP, Growth hormone releasing factor, analogs
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 90599-39-6DP, analogs 90830-28-7DP, 1-29-Somatoliberin (human pancreatic

islet), analogs 185744-56-3P 185744-57-4P 261619-10-7P, L-Leucinamide, N-[[(1R,2S)-2-ethylcyclopropyl]acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- 261619-56-1P, L-Leucinamide, N-[(cis-2-ethylcyclopropyl)acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- 261620-00-2P, L-Leucinamide, N-[[(1R,2R)-2-ethylcyclopropyl]acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- 261620-02-4P, L-Leucinamide, N-[[(3R)-3-methylcyclopentyl]acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- 261620-04-6P, L-Leucinamide, N-(bicyclo[4.1.0]hept-1-ylacetyl)-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- **261620-06-8P**, L-Leucinamide, N-[(2-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- **261620-11-5P*****, **L-Leucinamide, N-[(3-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT **75-11-6, Diiodomethane 108-59-8, Dimethyl malonate 108-94-1, Cyclohexanone, reactions 111-42-2, Diethanolamine, reactions 121-43-7,**

Trimethylborate 124-40-3, Dimethylamine, reactions 593-71-5, Chloroiodomethane 608-68-4, Dimethyl tartrate 693-03-8, Butyl magnesium bromide 867-13-0, Triethylphosphonoacetate 928-96-1, cis-3-Hexen-1-ol 928-97-2, trans-3-Hexen-1-ol 6672-30-6, Cyclopentanone, 3-methyl-, (3R)- 13368-65-5, Cyclohexanone, 3-methyl-, (3R)-
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 1552-92-7P, Acetic acid, cyclohexylidene-, ethyl ester 4426-47-5P, Butylboronic acid 4709-59-5P, 1-Cyclohexene-1-acetic acid, ethyl ester 24965-94-4P, Cyclohexanol, 3-methyl-, (1R,3R)- 63126-52-3P, Butanediamide, 2,3-dihydroxy-N,N,N',N'-tetramethyl-, [S-(R*,R*)]- 66529-34-8P, Cyclohexanol, 3-methyl-, methanesulfonate, (1R,3R)- 87626-08-2P, Cyclopropaneacetic acid, 2-ethyl-, (1R,2R)-rel- 131469-79-9P, Bicyclo[4.1.0]heptane-1-acetic acid 161344-85-0P, 1,3,2-Dioxaborolane-4,5-dicarboxamide, 2-butyl-N,N,N',N'-tetramethyl-, (4R,5R)- 173327-83-8P, Cyclopropaneethanol, 2-ethyl-, (1R,2R)- 252663-45-9P, Boron, butyl[[2,2'-(imino-κN)bis[ethanolato-κO]](2-)]-, (T-4)- 260983-17-3P, Cyclopropaneethanol, 2-ethyl- 260983-18-4P, Cyclopropaneethanol, 2-ethyl-, (1R,2S)- 260983-19-5P, Cyclopropaneacetic acid, 2-ethyl-, (1R,2R)- 260983-20-8P, Acetic acid, [(3R)-3-methylcyclopentylidene]-, ethyl ester 260983-21-9P, Cyclopentaneacetic acid, 3-methyl-, ethyl ester, (3R)- 260983-22-0P, Cyclopentaneacetic acid, 3-methyl-, (3R)- 260983-23-1P, Bicyclo[4.1.0]heptane-1-acetic acid, ethyl ester 260983-24-2P, Propanedioic acid, [(1S,3R)-3-methylcyclohexyl]-, dimethyl ester 260983-25-3P, Propanedioic acid, [(1S,3R)-3-methylcyclohexyl]- 260983-26-4P, Cyclohexaneacetic acid, 3-methyl-, (1S,3R)- 261354-51-2P, Cyclopropaneacetic acid, 2-ethyl-, (1R,2S)-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Brazeau; US 6020311 A 2000 HCAPLUS
(2) Ibea; US 5861379 A 1999 HCAPLUS
(3) Ibea; US 5939386 A 1999 HCAPLUS

L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:175935 HCAPLUS
DN 132:217510
ED Entered STN: 17 Mar 2000
TI Growth hormone releasing factor analogs with increased biological potency and their therapeutic uses
IN Gravel, Denis; Habi, Abdelkrim; Brazeau, Paul
PA Theratechnologies Inc., Can.
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C12N015-16
ICS C07K014-60; A61K038-25; G01N033-68
CC 2-10 (Mammalian Hormones)
Section cross-reference(s): 1
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000014236	A2	20000316	WO 1999-CA816	19990907

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6020311	A	20000201	US 1998-148982	19980908	
US 6458764	B1	20021001	US 1999-389486	19990903	
CA 2342070	AA	20000316	CA 1999-2342070	19990907	
AU 9955007	A1	20000327	AU 1999-55007	19990907	
AU 755852	B2	20021219			
BR 9913515	A	20010605	BR 1999-13515	19990907	
EP 1109909	A2	20010627	EP 1999-941349	19990907	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002524472	T2	20020806	JP 2000-568979	19990907	
PRAI US 1998-148982	A	19980908			
US 1999-389486	A	19990903			
US 1995-453067	B2	19950526			
US 1996-651645	B2	19960522			
US 1996-702113	A2	19960823			
US 1996-702114	A2	19960823			
WO 1999-CA816	W	19990907			

OS MARPAT 132:217510

AB The present invention relates to chimeric fatty body-GRF analogs with increased biol. potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include a hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity. Thus, a series of 7 human GRF analogs with a variety of cycloalkyl-or phenyl-containing acyl groups attached to the N-terminus were synthesized. Relative to the human GRF control, these analogs significantly increased insulin-like growth factor 1 (IGF-1) levels in pig serum on day 6. Increased serum IGF-1 levels were observed on day 3 for two of the analogs.

ST growth hormone releasing factor analog

IT Proteins, general, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(anabolism; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Bone, disease
(fracture, healing of; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Antiobesity agents
Wound healing
(growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Diagnosis
(mol.; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Dwarfism
(pituitary, retardation of; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Growth, animal

(retardation of; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 9034-39-3DP, Growth hormone releasing factor, analogs 185744-56-3P 185744-57-4P 261619-10-7P 261619-56-1P 261620-00-2P 261620-02-4P 261620-04-6P **261620-06-8P 261620-11-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 9002-72-6, Growth hormone
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 75-11-6, Diiodomethane 108-59-8, Dimethyl malonate 108-94-1, Cyclohexanone, reactions 111-42-2, Diethanolamine, reactions 121-43-7, Trimethylborate 124-40-3, Dimethylamine, reactions 593-71-5, Chloroiodomethane 608-68-4, Dimethyl tartrate, reactions 693-03-8, Butyl magnesium bromide 867-13-0, Triethylphosphonoacetate 928-96-1, cis-3-Hexen-1-ol 928-97-2, trans-3-Hexen-1-ol 6672-30-6 13368-65-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 1552-92-7P 4426-47-5P, Butylboronic acid 4709-59-5P 24965-94-4P 63126-52-3P 66529-34-8P 87626-08-2P 131469-79-9P, Bicyclo[4.1.0]heptane-1-acetic acid 161344-85-0P 173327-83-8P 252663-45-9P 260983-17-3P 260983-18-4P 260983-19-5P 260983-20-8P 260983-21-9P 260983-22-0P 260983-23-1P 260983-24-2P 260983-25-3P 260983-26-4P 261354-51-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 90599-39-6 90830-28-7, 1-29-Somatoliberin (human pancreatic islet)
RL: PRP (Properties)
(unclaimed protein sequence; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

=> b uspatall
FILE 'USPATFULL' ENTERED AT 11:22:32 ON 11 FEB 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:22:32 ON 11 FEB 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn 14 DISPLAY FOR USPATALL

L4 ANSWER 1 OF 1 USPATFULL on STN
AN 2002:254337 USPATFULL
TI GRF analogs with increased biological potency
IN Gravel, Denis, St-Lambert, CANADA
Habi, Abdelkrim, Anjou, CANADA
Brazeau, Paul, Montreal, CANADA
PA Theratechnologies Inc., Montreal, CANADA (non-U.S. corporation)
PI US 6458764 B1 20021001
AI US 1999-389486 19990903 (9)
RLI Continuation-in-part of Ser. No. US 1998-148982, filed on 8 Sep 1998, now patented, Pat. No. US 6020311 Continuation-in-part of Ser. No. US

1996-702113, filed on 23 Aug 1996, now patented, Pat. No. US 5939386, issued on 17 Aug 1999 Continuation-in-part of Ser. No. US 1996-702114, filed on 23 Aug 1996, now patented, Pat. No. US 5861379, issued on 19 Jan 1999 Continuation-in-part of Ser. No. US 1996-651645, filed on 22 May 1996, now abandoned Continuation-in-part of Ser. No. US 1995-453067, filed on 26 May 1995, now abandoned

DT Utility
FS GRANTED
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed, Abdel A.
LREP Crowell & Moring LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1550
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **261620-06-8P**, L-Leucinamide, N-[(2-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- **261620-11-5P**, L-Leucinamide, N-[(3-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L-α-glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl-
(preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

=> b home
FILE 'HOME' ENTERED AT 11:23:34 ON 11 FEB 2004

=>